{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Terman SW"],"funding":["National Institute of Neurological Disorders and Stroke","University of Michigan","NIA NIH HHS","Epilepsy Society","NINDS NIH HHS","National Institutes of Health","National Institute on Aging"],"pagination":["107615"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12849773"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["217"],"pubmed_abstract":["<h4>Objectives</h4>Antiseizure medications (ASMs) represent standard treatment for epilepsy. Yet, ASMs have adverse effects, and seizure risk decreases with longer seizure freedom. Guidelines consider ASM withdrawal after a period of seizure freedom. However, work exploring how patients approach this decision is scarce. We inquired what decision-making factors patients feel are relevant to ASM discontinuation.<h4>Methods</h4>We conducted a mixed-methods study of adults seen for epilepsy, at least one-year seizure-free, across three academic institutions. This included a semi-structured interview script assessing attitudes towards seizures, ASMs, and ASM discontinuation.<h4>Results</h4>We interviewed 32 participants. Factors supporting ASM discontinuation included current side effects (e.g."],"journal":["Epilepsy research"],"pubmed_title":["Antiseizure medication discontinuation: A mixed-methods exploration of factors considered by patients when approaching decision-making."],"pmcid":["PMC12849773"],"funding_grant_id":["K23 AG081463","K23 NS126495","K23NS126495"],"pubmed_authors":["Kalia N","Mortati K","Manuel K","Burke JF","Silva JM","Kuster M","Grant AC","Brand A","Lee J","Tolmasov A","O'Kula SS","Terman SW","Hill CE","Patel PS","Reid M","Dugan M"],"additional_accession":[]},"is_claimable":false,"name":"Antiseizure medication discontinuation: A mixed-methods exploration of factors considered by patients when approaching decision-making.","description":"<h4>Objectives</h4>Antiseizure medications (ASMs) represent standard treatment for epilepsy. Yet, ASMs have adverse effects, and seizure risk decreases with longer seizure freedom. Guidelines consider ASM withdrawal after a period of seizure freedom. However, work exploring how patients approach this decision is scarce. We inquired what decision-making factors patients feel are relevant to ASM discontinuation.<h4>Methods</h4>We conducted a mixed-methods study of adults seen for epilepsy, at least one-year seizure-free, across three academic institutions. This included a semi-structured interview script assessing attitudes towards seizures, ASMs, and ASM discontinuation.<h4>Results</h4>We interviewed 32 participants. Factors supporting ASM discontinuation included current side effects (e.g.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-16T07:18:34.265Z","creation":"2026-06-16T03:09:39.401Z"},"accession":"S-EPMC12849773","cross_references":{"pubmed":["40540761"],"doi":["10.1016/j.eplepsyres.2025.107615"]}}